Outpatient Treatment of Infantile Hemangiomas With Propranolol: A Prospective Study

Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day‐care hospitalization setting

“…The absence of severe side‐effects in any of the numerous reports of propranolol use supports the safety of propranolol. Their absence in outpatient settings with various methods of follow‐up supports the safety of ambulatory monitoring …”

“…Their absence in outpatient settings with various methods of follow-up supports the safety of ambulatory monitoring. [31][32][33] Based on the results of our study, we suggest that in children with infantile haemangioma, propranolol may be initiated at an escalating dose of 0.5-2 mg/kg over 3 days under haemodynamic surveillance before and 1 h after onset of treatment and dose adjustment. Since 2014, we started treating IH at an ambulatory approach which has yielded good results with a high safety profile.…”

Medical, Surgical, and Wound Care Management of Ulcerated Infantile Hemangiomas: A Systematic Review

“…Of these 191 patients successfully treated with propranolol, 10 had previously been trialed on systemic corticosteroids and experienced no wound healing or incomplete healing. 2,[8][9][10][11][12] Hyperkalemia was reported in 3 patients, although none were severe enough to necessitate discontinuation of therapy. [13][14][15] In 1 case, laboratory tumour lysis syndrome due to propranolol therapy was diagnosed on the basis of hyperkalemia and hyperphosphatemia in the absence of clinical symptoms.…”

Treatment of periorbital infantile haemangiomas: A systematic literature review on propranolol or steroids

“…Corticosteroids have been the mainstay of IH treatment for many years . However, the efficacy of propranolol for the treatment of IH has recently been demonstrated, and numerous reports have suggested that oral propranolol holds high promise for IH treatment …”